Please login to the form below

Not currently logged in
Email:
Password:

GLP-1

This page shows the latest GLP-1 news and features for those working in and with pharma, biotech and healthcare.

Lilly’s Trulicity scores CV reduction indication in the US

Lilly’s Trulicity scores CV reduction indication in the US

The once-weekly GLP-1 agonist has been available in the US since 2014, when it first gained FDA approval to improve glycaemic control in adults with type 2 diabetes. ... The new MACE approval could help Lilly in its fight for market share with other

Latest news

  • New drugs drive Novo Nordisk despite insulin price pressures New drugs drive Novo Nordisk despite insulin price pressures

    This included a boost from GLP-1 agonist  Ozempic (semaglutide) which has been climbing solidly since its launch, as demand increases for the drug. ... For Novo, this pressure has been reflected in its adjusted operating profit growth prediction for the

  • Givlaari, Rybelsus lead crowded CHMP recommendations Givlaari, Rybelsus lead crowded CHMP recommendations

    Joining Givlaari with a positive recommendation was  Rybelsus (semaglutide), Novo Nordisk’s once-daily oral formulation of its injectable GLP-1 agonist semaglutide.

  • Novo Nordisk gets MACE prevention claim for Ozempic in US Novo Nordisk gets MACE prevention claim for Ozempic in US

    That showed a 12% reduction in MACE with the GLP-1 drug, but included patients both with and without cardiovascular disease so isn’t directly comparable. ... For now, it’s the only GLP-1 drug on the market that can be given as a daily oral dose.

  • Novo bolstered by new diabetes, obesity products Novo bolstered by new diabetes, obesity products

    The once-weekly injectable GLP-1 agonist has continued to offset declines of Novo’s older drugs, including the one-daily shot Victoza (liraglutide). ... It is the first oral alternative to injectable GLP-1 agonists, and has also been touted by Novo as

  • Novo Nordisk taps Noom for digital help with its push into obesity Novo Nordisk taps Noom for digital help with its push into obesity

    Novo Nordisk is already making headway in the obesity therapy market with injectable GLP-1 agonist Saxenda (liraglutide), which made $390m in sales in the first half of the year, up ... its once-weekly injectable and once-daily oral formulations of follow

More from news
Approximately 15 fully matching, plus 149 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    7. NovoNordisk’s Rybelsus is an oral once-daily formulation of semaglutide, a long-acting glucagon-like peptide (GLP)-1 analog. ... Upon interaction with the GLP-1 receptor, it stimulates the secretion of insulin in a glucose-dependent manner.

  • Harnessing commercial innovation Harnessing commercial innovation

    These efforts moved up a gear last year when Novo decided to enter into phase III trials with an oral GLP-1.

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    like peptide-1 (GLP-1), a hormone that works independently of insulin to stimulate glucose release. ... Oramed - whose technology relies on encapsulating the peptide or protein and delivering it alongside enzyme inhibitors and permeation enhancers - has

  • Deal Watch November 2015 Deal Watch November 2015

    Included in the package are three products: a weekly insulin, a fixed weekly dose combination of GLP-1-RA/insulin and efpeglenatide, a long acting glucagon like peptide-1 receptor agonist. ... 6, 546. Hanmi Pharmaceutical. Sanofi. Licence. Three diabetes

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    400. Inarcia therapeutics / Investors. Synthetic royalty rights. ICTA650 extended sub-cutaneous delivery of GLP-1 for T2DM.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

The big issue
Whether you want to lead or follow, you need to understand the elephant in the C-suite...
INFOGRAPHIC 02: The Importance of clinical study websites
Here’s a infographic of why clinical study websites are important to patient recruitment and retention strategies…...
Working with, Advocating for, and Empowering Patients
A holistic view of how to work with patients virtually...

Infographics